Results 51 to 60 of about 728 (161)

Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis [PDF]

Exploration of Cardiology
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (
Ayesha Aman, Bisma Akram, Arfa Akram, Momina Maham, Eisha Tariq, Aimen Hassan, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Malik Waleed Zeb Khan   +9 more
doaj   +1 more source

Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy [PDF]

Patients with obstructive hypertrophic cardiomyopathy (oHCM) have increased risk of arrhythmia, stroke, heart failure, and sudden death. Contemporary management of oHCM has decreased annual hospitalization and mortality rates, yet patients have worsening
Olivotto, Iacopo
core   +6 more sources

Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies

Frontiers in Physiology, 2022
Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and sudden death.
Masataka Kawana, Masataka Kawana, James A. Spudich, Kathleen M. Ruppel   +3 more
doaj   +1 more source

Old and new therapeutic solutions in the treatment of hypertrophic cardiomyopathy [PDF]

, 2023
Hypertrophic cardiomyopathy (HCM) is a genetic disease of the myocardium that is relatively common in the general population, with an autosomal dominant inheritance as a genetic basis.
Autore, Camillo, Francia, Pietro, Musumeci, Beatrice, Tini, Giacomo   +3 more
core   +1 more source

Myosin Modulators Mavacamten and Aficamten Inhibit Cardiac Contractility Through Different Mechanisms

Journal of Molecular and Cellular Cardiology Plus
Saffie Mohran, Kristina Kooiker, Galina Flint, Max Mahoney-Schaefer, Weikang Ma, Timothy McMillen, Thomas Irving, Michael Regnier, Farid Moussavi-Harami   +8 more
doaj   +2 more sources

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten

Therapeutic Advances in Chronic Disease, 2022
Hypertrophic cardiomyopathy (HCM) is a common genetic disorder characterised by unexplained left ventricular hypertrophy. Left ventricular outflow tract obstruction is an integral component of the disease, often resulting in significant symptoms, but ...
Susan Mathai, Lynne Williams
doaj   +1 more source

Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving Disopyramide: REDWOOD-HCM Cohort 3 [PDF]

, 2023
No abstract ...
Abraham, Theodore P., Ahmad, Masri, Choudhury, Lubna, Coats, Caroline J., Fifer, Michael A., Heitner, Stephen B., Jacoby, Daniell, Kupfer, Stuart, Malik, Fady i., Martins, Maron, Meng, Lisa, Olivotto, Iacopo, Owens, Anjalit, Rader, Florian, Sohn, Regina, Solomon, Scott D., Symanski, John D., The Redwood-HCM Investigators,, Tower-Rader, Albree, Turer, Aslan T., Watkins, Hugh C., Wohltmann, Amy, Wong, Timothy C.   +22 more
core   +1 more source

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM. [PDF]

Journal of Cardiac Failure
Ahmad Masri, M. Sherrid, L. Choudhury, P. García-Pavía, Christopher M. Kramer, R. Barriales-Villa, R. Cooper, P. Elliott, S. M. Hegde, M. Maron, M. Nassif, A. Oręziak, A. Owens, S. Solomon, A. Tower-Rader, S. Heitner, D. Jacoby, S. Kupfer, F. Malik, C. Melloni, Tyrell Simkins, J. Wai, S. Saberi   +22 more
semanticscholar   +3 more sources

Metabolite‐sensitive cross‐bridge models of human atria reveal the impact of diabetes on muscle mechanoenergetics

The Journal of Physiology, EarlyView.
Abstract figure legend In this study, we used mathematical modelling to explore the effect of diabetes on muscle mechanoenergetics. Our parameterisation of cross‐bridge models using data from non‐diabetic and diabetic human atrial tissues revealed lower values for cross‐bridge stiffness, detachment rates, attachment rates and lower ATP sensitivity in ...
Julia H. Musgrave, June‐Chiew Han, Marie‐Louise Ward, Andrew J. Taberner, Kenneth Tran   +4 more
wiley   +1 more source

Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights

The Journal of Physiology, EarlyView.
Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies. Printed with permission from ®Anita Impagliazzo Medical Illustration. [Correction added on 2 March
Silvia Marchianò, Miguel Martín‐Aragón Baudel, Charlotte E. R. Smith, Gonzalo Hernandez Hernandez, Donald M. Bers, Patrick M. Boyle, Dobromir Dobrev, Shanna Hamilton, Osama F. Harraz, Na Li, Thomas A. Longden, William E. Louch, Madeline Nieves‐Cintron, Matthew A. Nystoriak, Walter Lee Murfee, Przemysław B. Radwański, Swapnil K. Sonkusare, Manuel F. Navedo, Eleonora Grandi   +18 more
wiley   +1 more source